Jeroen Mebis

TL;DR: 1 year of extended adjuvant therapy with neratinib, administered after chemotherapy and trastuzumab, significantly reduced the proportion of clinically relevant breast cancer relapses-ie, those that might lead to death, such as distant and locoregional relapses outside the preserved breast-without increasing the risk of long-term toxicity.

TL;DR: The BRIM8 study evaluated adjuvant vemurafenib monotherapy in patients with resected, BRAFV600 mutation-positive melanoma and the result was not significant because of the prespecified hierarchical prerequisite for the primary disease-free survival analysis of cohort 2 to show a significant health benefit.

TL;DR: Immediate ZOL administration effectively prevented BMD loss and increased BMD in postmenopausal women with HR(+) EBC receiving adjuvant letrozole, regardless of BMD status at baseline.

TL;DR: Overall both the GFI and the G8 questionnaire were able to separate older patients with cancer with a normal and abnormal CGA, however at the expense of the specificity.

TL;DR: Extended intermittent use of adjuvant letrozole in postmenopausal women with hormone receptor-positive, lymph node- positive, and operable breast cancer for which they had undergone local treatment and had completed 4-6 years of adjUvant endocrine therapy is hypothesised to improve breast cancer outcome compared with continuous use of letroZole.